Publikationen

The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines

Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte JH, Bachmann HS.
BMC Cancer. 2019 Mar 18;19(1):243. doi: 10.1186/s12885-019-5439-1.
PMID: 30885150

Spatial analysis of p63, K5 and K7 defines two groups of progenitor cells that differentially contribute to the maintenance of normal sebaceous glands, extraocular sebaceous carcinoma and benign sebaceous tumors

Boecker W, Reusch M, Mielke V, Reusch U, Loening T, Tiemann M, Buchwalow I.
J Dermatol. 2019 Jan 21. doi: 10.1111/1346-8138.14765. [Epub ahead of print]
PMID: 30663115

New Insight into the Role of Nitric Oxide Pathways in Pancreas

Buchwalow I, Schnekenburger J, Samoilova V, Boecker W, Neumann J, Tiemann K. Acta Histochem Cytochem, 2018 Dec 20;51 (6):167-172. Doi: 10.1267/ahc.18028.Epub 2018 Nov 3. PMID: 30647491

The PDL1-inducible GTPase Arl4d controls T effector function by limiting IL-2 production

Tolksdorf F, Mikulec J, Geers B, Endig J, Sprezyna P, Heukamp LC, Knolle PA, Kolanus W, Diehl L.
Sci Rep. 2018 Oct 31;8(1):16123. doi: 10.1038/s41598-018-34522-4.
PMID: 30382149

Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns

Hallas C, Preukschas M, Tiemann M.
Leuk Res. 2019 Jan;76:107-111. doi: 10.1016/j.leukres.2018.10.003. Epub 2018 Oct 10.
PMID: 30360939

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.
J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8. No abstract available.
PMID: 30205165

Spatially correlated phenotyping reveals K5-positive luminal progenitor cells and p63-K5/14-positive stem cell-like cells in human breast epithelium

W. Boecker, L. van Horn, G. Stenman, C. Sturken, U. Schumacher, T. Loening, L. Liesenfeld, E. Korsching, D. Glaser, K. Tiemann, I. Buchwalow
Lab Invest, (2018) Volume 98 (8) 65-1075

Poster

Die MYD88 L265P-Mutation: Ein Werkzeug für die Differentialdiagnose von indolenten Lymphomen mit überlappenden klinisch-pathologischen Eigenschaften? Michael Preukschas Marina Lebherz, Cora Hallas, Markus Tiemann. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie, 10.-14. Oktober 2014 Hamburg, Germany

Tumor-infiltrierende Lymphozyten in kolorektalen Adenokarzinomen:  Die Entwicklung der Immunantwort in den verschiedenen Tumorstadien. Merle Stamm, Cora Hallas, Markus Falk, Markus Tiemann. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie, 10.-14. Oktober 2014 Hamburg, Germany

Distribution of driver mutations in a northern German cohort of melanoma patients and limitations of different methods for BRAF testing. Markus Falk, Tobias Berg, Hans-Joachim Schulze, Michael Fluck, Markus Tiemann 8th World Congress of Melanoma, July 17–20 2013, Hamburg, Germany

Incidence of molecular targets (EGFR-mutation, EML4-Alk, BRAF and KRAS) in metastatic NSCLC in a certified lung cancer hospital. Volker Halbfass, Markus Falk, Regina Prenzel, Hans-Georg Dercken, Douglas Scriba, Markus Tiemann, Frank Griesinger 14th Conference of Lung Cancer, 3-7 July 2011, Amsterdam, Netherlands

Various Mutations In JAK2 Exon 12 Induce Divergent Bone Marrow Alterations Hallas C, Schulte C, Heidorn K, Tiemann M 53 ASH Annual Meeting and Exposition 2011, Abstract 4096

to top icon